IQVIA Holdings Inc. — FY2017 Form 10-K
Business context and period. This annual report covers the fiscal year ended December 31, 2017; it also reports fourth-quarter results. IQVIA provides healthcare information, technology and contract research services through Commercial Solutions, Research & Development Solutions (R&D), and Integrated Engagement Services. The company changed its name from Quintiles IMS Holdings to IQVIA in November 2017. FY2017 comparisons with 2016 are materially affected by the October 2016 IMS Health merger: 2017 includes a full year of the combined business, while 2016 includes IMS Health only after the merger closed.
Financial performance
| Metric | FY2017 | FY2016 | Context |
|---|---|---|---|
| Revenue, excluding reimbursed expenses | $8.060 billion | $5.364 billion | Up 50.3%; management attributed most of the increase to the merger. |
| Total revenue, including reimbursed expenses | $9.739 billion | $6.878 billion | Reimbursed expenses were $1.679 billion in 2017 and are largely pass-through costs. |
| Operating income | $719 million | $642 million | Operating margin on revenue excluding reimbursed expenses was about 8.9%, versus 12.0%; higher acquired-asset amortization was a major factor. |
| Net income attributable to IQVIA | $1.309 billion | $115 million | 2017 was lifted substantially by a provisional tax benefit related to the Tax Cuts and Jobs Act. |
| Diluted EPS | $5.88 | $0.76 | Not representative of underlying operating growth because of the tax benefit. |
| Cash from operating activities | $970 million | $860 million | Increase of $110 million; working-capital and payment timing also affect cash conversion. |
| Capital expenditures | $369 million | $164 million | Includes property, equipment and software purchases. |
| Cash and cash equivalents | $959 million | $1.198 billion | Only $147 million was held in the United States at year-end. |
| Total debt | $10.269 billion | $7.219 billion | Debt increased following financing activity and the merger; $471 million remained available on the revolving credit facility. |
Fourth-quarter results
For Q4 2017, revenue was $2.161 billion, operating income $203 million, net income $1.084 billion, and net income attributable to IQVIA $1.076 billion. Diluted EPS was $5.02. The unusually high quarterly earnings primarily reflect the year-end tax-law benefit, rather than a comparable increase in operating performance.
Segments and operating indicators
- Commercial Solutions: revenue of $3.630 billion and segment profit of $1.010 billion. Growth versus 2016 was dominated by the merger contribution.
- R&D Solutions: revenue of $3.647 billion, up 4.9%, and segment profit of $997 million. Net new business was $4.54 billion for the twelve months ended December 31, 2017; ending backlog was $10.54 billion.
- Integrated Engagement Services: revenue of $783 million, down 1.8%, and segment profit of $73 million. The company cited lower demand and cancellations in Japan and North America.
Material changes and unusual items
- The merger makes reported year-over-year revenue growth and segment mix comparisons non-comparable without considering the partial-year contribution in 2016.
- Depreciation and amortization rose to $1.011 billion from $289 million, largely due to amortization of acquired merger-related intangible assets. Restructuring costs were $63 million; merger-related costs were nil in 2017 versus $87 million in 2016.
- The company recorded a $40 million impairment related to Encore and sold that business in July 2017. FY2017 also included $19 million of debt-extinguishment loss.
- The Tax Act produced a provisional $977 million deferred tax benefit; the total income tax benefit was $987 million. Management said the tax accounting remained subject to finalization and could change.
- IQVIA repurchased approximately 30.9 million shares for $2.620 billion in 2017. The board subsequently increased the post-merger repurchase authorization; the filing reports $1.7 billion remaining after that February 2018 increase.
Liquidity, debt and outlook
Management stated that cash, expected operating cash flows and access to revolving and receivables facilities should fund operating needs, capital expenditures and debt obligations for at least the next 12 months. At year-end, total debt was $10.269 billion and the company was in material compliance with its financial covenants. Debt agreements include leverage and interest-coverage tests, collateral provisions and restrictions on dividends and other actions. Variable-rate debt and foreign-currency exposure remain relevant risks.
The filing provides no specific company revenue or earnings guidance. Management described growth opportunities in data analytics, clinical development, real-world evidence, technology and broader healthcare markets, alongside planned continued investment and selective acquisitions. Its market estimates and industry forecasts are not company guidance.
Risks, contingencies and governance
- Clinical-trial contracts may be delayed, reduced or terminated; backlog is not a guarantee of future revenue. Cost overruns and unapproved scope changes can pressure margins.
- The business depends on third-party data suppliers and on protecting sensitive health information. Privacy-law changes, cybersecurity incidents or loss of data access could disrupt services and damage client relationships.
- Competition, client consolidation, foreign-exchange movements, regulatory changes, acquisition integration and the company’s substantial indebtedness may affect results.
- Legal matters include an appeal of a Korean privacy-law civil case, a South Korean prosecution involving IMS Korea, a U.S. government contract voluntary-disclosure matter whose ultimate liability could exceed reserves, and Veeva counterclaims seeking damages in excess of $200 million. Management said it did not expect pending proceedings overall to have a material adverse effect, while noting unfavorable outcomes could be material.
- Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2017; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Separate merger-driven growth from organic growth, especially in Commercial Solutions, and assess comparability against 2016’s partial-year merger contribution.
- Evaluate normalized earnings and tax assumptions after the provisional Tax Act benefit; verify the final tax accounting and its cash-tax implications.
- Track debt, interest expense, covenant headroom, refinancing needs and the extent to which share repurchases compete with debt reduction and investment.
- Monitor R&D backlog conversion, cancellations, net new business and the weaker Integrated Engagement Services trend.
- Review developments in the Korean privacy proceedings, the GSA contract matter and Veeva litigation, including any changes to reserves or disclosed exposure.